|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 2.05 Billion
|
|
Market Size (2030)
|
USD 3.37 Billion
|
|
CAGR (2025-2030)
|
8.64%
|
|
Fastest Growing Segment
|
Phase III
|
|
Largest Market
|
West India
|
Market Overview
India Clinical Trials Market was valued at USD 2.05 Billion in 2024 and is anticipated to reach USD 3.37 Billion by 2030, with a CAGR of 8.64% during 2025-2030. The Clinical Trials Market refers to the global industry that operates and manages clinical trials, which are crucial research
investigations. In these trials, individuals voluntarily participate to evaluate new treatments, interventions, or tests aimed at preventing, detecting, treating, or managing various diseases or medical conditions. By conducting these trials,
researchers aim to determine not only the safety and effectiveness but also the
scalability of new drugs or treatments, ensuring their potential impact on a
larger scale.
This
market encompasses a wide range of stakeholders, including pharmaceutical
companies, contract research organizations, healthcare providers, academic institutes,
and more. All these entities collaborate in a concerted effort, playing a
pivotal role in accelerating the process of drug discovery and development.
Through their collective endeavors, innovative treatments can be made available
to patients worldwide, addressing unmet medical needs and improving health
outcomes across diverse populations. This continuous pursuit of knowledge and
advancements in clinical research ultimately leads to breakthroughs that shape
the future of medicine and benefit humanity as a whole.
Key Report Takeaway
- Phase III trials led in revenue share, driven by large patient enrollment, long study duration, and high operational costs
- Phase I trials are expected to grow steadily as pharmaceutical and biotechnology firms increase research and development investments
- Interventional trials dominated by study design, supported by strong reliability in evaluating drug safety and treatment effectiveness
- Western India, especially Maharashtra, emerged as a leading hub due to strong research infrastructure, skilled professionals, and diverse patient population
Key Market Drivers
Growing
Demand for Clinical Trials
India is witnessing a steady rise in demand for clinical trials as healthcare systems emphasize evidence-based treatment and validated medical innovation. Clinical trials evaluate the safety and effectiveness of new drugs, medical devices, and treatment protocols before large-scale adoption. India’s diverse genetic pool, varied lifestyles, and wide disease patterns provide researchers with a strong base for inclusive and comprehensive studies across population groups. Global registry data reported 2,260 phase-1 trials registered in India between 2008-2022, showing steady expansion in early-stage research capability.
India also offers a strong research ecosystem that attracts global pharmaceutical companies seeking trial locations. The country hosts advanced hospitals, research institutes, and an experienced medical workforce capable of managing complex studies. Regulatory clarity has improved after the introduction of the New Drugs and Clinical Trials Rules 2019, which defined approval timelines such as 90 days for global trials and 30 days for investigational drugs developed locally. This framework has strengthened transparency, ethical oversight, and confidence among international sponsors.
Rising clinical research activity also produces economic benefits by creating skilled employment and supporting high-value research services. Organizations such as Syngene International Limited illustrate this growth, reporting ₹3,489 crore revenue from operations in FY24 and employing more than 8,000 professionals. As pharmaceutical innovation expands and global companies seek diverse trial populations, India’s clinical trial ecosystem is expected to play a larger role in medical research, healthcare innovation, and economic development..
High
R&D Expenditure of the Pharmaceutical Industry
The pharmaceutical industry’s substantial investment in Research and Development (R&D) is driving an upsurge in the demand for clinical trials in India. With the relentless pursuit of developing new drugs and treatments, companies recognize the necessity for comprehensive and rigorous clinical trials. India, with its vast and diverse patient population, presents an ideal environment for these trials, enabling the generation of robust and diverse data essential for scientific advancements. Sun Pharma reported total R&D expenditure of 31,775.9 million rupees in FY24, illustrating the scale of investment that ultimately needs rigorous clinical validation through trials.
Conducting clinical trials in India often proves to be cost-effective, a significant advantage for companies grappling with the high costs of R&D. The government's supportive regulations and the availability of skilled medical professionals further contribute to India's attractiveness as a preferred destination for clinical trials. This favorable ecosystem fosters collaboration between pharmaceutical companies, research institutions, and healthcare providers, reinforcing India's position as a prominent player in the global pharmaceutical landscape. India’s New Drugs and Clinical Trials Rules 2019 lays out defined review timelines such as 90 days for global clinical trials and 30 days for investigational new drugs discovered in India, with provision to proceed if there is no communication within the specified period.
By investing in cutting-edge research and development, the pharmaceutical industry not only drives innovation but also fuels the growth of clinical trials in India. This symbiotic relationship strengthens India's contribution to the global healthcare ecosystem, ultimately benefiting patients worldwide. Syngene reported FY24 revenue from operations of 3,489 crore rupees and a workforce of 8,146 as of March 31, 2024, signaling how India’s clinical research and development ecosystem can translate into scaled, high-skill employment.
Rising
Prevalence of Diseases
India is witnessing a rapid acceleration in the demand for clinical trials as the prevalence of diseases continues to surge. The incidence of diseases, particularly chronic conditions like diabetes and heart disease, is on the rise due to shifting lifestyle patterns and the increasing life expectancy of the population. This challenging situation necessitates the urgent need for novel treatments and therapies, thus driving the demand for clinical trials. Government of India has cited ICMR INDIAB 17 estimates that India has 101 million people living with diabetes and 136 million with prediabetes, underscoring the scale of chronic disease burden that can intensify clinical trial activity.
India's rich and diverse genetic pool makes it an ideal ground for conducting these trials. The diversity allows for a more comprehensive understanding of how treatments may affect different genetic makeups, leading to personalized and targeted therapies. This unique advantage positions India as a valuable contributor to global medical research. The increased availability of highly skilled healthcare professionals, coupled with an enhanced regulatory framework, further supports the rising demand for clinical trials in India. The expertise of these professionals ensures the proper conduct and supervision of trials, adhering to rigorous ethical standards and safety protocols. To expand the trained workforce that supports trial delivery, the National Medical Commission approvals for 2024-25 have been reported to take the total number of medical institutions to 816 and overall MBBS seats to 1,37,600.
The country's vast patient population provides a broad base for recruitment, which is often a critical challenge in conducting clinical trials. With a large and diverse population, researchers have access to a wide range of participants, enabling more comprehensive and statistically significant results. Tthe combination of increased disease prevalence, India's advantageous genetic diversity, the presence of skilled healthcare professionals, and a large patient population are all contributing significantly to the growing demand for clinical trials in the country. This trend highlights India's potential to play a pivotal role in advancing medical research and improving healthcare outcomes globally. The Clinical Trials Registry India held records of 59,532 trials as of November 03, 2023, indicating the scale of registered clinical research activity supported by India’s recruitment base.
Increasing
Research and Development Promoting Outsourcing
In
India, the surge in demand for clinical trials can be inextricably linked to
the rise in research and development (R&D) outsourcing. As global
pharmaceutical companies seek cost-effective alternatives to drive innovation,
India emerges as an attractive destination due to its resource-rich
capabilities and low operational cost. With its vast pool of healthcare
professionals and state-of-the-art infrastructure, India offers a conducive
environment for conducting cutting-edge clinical research. The
country's substantial patient population and diverse gene pool provide a unique
advantage, offering a broader data set for clinical trials. This diverse
genetic landscape allows researchers to explore the efficacy of new treatments
and therapies across different genetic profiles, ultimately leading to
personalized healthcare solutions.
Adding
to India's appeal is the government's commitment to improving the regulatory
environment and enhancing ethical guidelines. By implementing robust
regulations and stringent quality control measures, the Indian government
ensures the highest standards of patient safety and data integrity in clinical
trials. This commitment further bolsters the confidence of global entities in
outsourcing their R&D activities to India. The rapid growth
of Contract Research Organisations (CROs) in India has propelled the country's
position in the global clinical trials landscape.
These CROs provide
specialized expertise, advanced infrastructure, and a skilled workforce, making
India an ideal hub for conducting clinical trials across various therapeutic
areas. In essence, the interplay of these factors creates a highly conducive
environment fostering the proliferation of clinical trials in India. This not
only brings about significant contributions to global healthcare advancements
but also positions India as a leading destination for cutting-edge research and
innovation in the pharmaceutical industry.
Download Free Sample Report
Key Market
Challenges
Lack
of Skilled Workforce in Clinical Research
India’s clinical research sector faces a shortage of trained professionals capable of managing complex trial processes and regulatory requirements. Clinical trials require specialists who understand advanced analytical tools, medical terminology, and ethical guidelines. Current academic programs are not producing enough trained researchers to meet the growing needs of pharmaceutical and biotechnology organizations. This shortage affects the pace of clinical research activities and limits the country’s ability to conduct large-scale trials efficiently.
Workforce limitations also influence global investment decisions in clinical research. International pharmaceutical companies prefer locations with a strong pool of trained investigators, data managers, and regulatory experts. When this talent base remains limited, organizations hesitate to expand research operations or initiate new studies in the country. As a result, India’s potential to grow as a global clinical research destination faces constraints, even though the country offers strong patient diversity and healthcare infrastructure.
Strengthening education and training programs in clinical research can help address this gap. Universities, research institutes, and industry stakeholders need to promote specialized programs that prepare professionals for clinical trial management and regulatory compliance. Increasing awareness about career opportunities in clinical research may also encourage more students to enter the field. Expanding the skilled workforce will support medical innovation, attract global research investment, and strengthen India’s role in clinical development activities.
Stringent
Regulations for Patient Enrollment
Strict patient enrollment requirements also present challenges in conducting clinical trials in India. Regulations require participants to meet defined eligibility criteria related to age, health condition, and medical history. These rules aim to protect trial participants and maintain reliable research outcomes. Participants must also provide informed consent after receiving detailed information about possible risks and benefits associated with the trial.
While these safeguards protect participant welfare, the enrollment process can become lengthy and complex. Many potential volunteers hesitate to participate because of concerns about safety, medical procedures, or trial commitments. This hesitation reduces the available patient pool and slows the progress of clinical research projects. Delays in enrollment often extend trial timelines and increase research costs for pharmaceutical sponsors.
As enrollment becomes more challenging, some research organizations explore countries with faster recruitment processes. This shift may limit India’s participation in global clinical studies despite its strong patient diversity and medical expertise. Balancing patient protection with efficient enrollment procedures remains important for sustaining clinical research activity and encouraging greater participation in medical innovation.
Key Market Trends
Adoption
Of New Technology in Clinical Research
The
adoption of new technology in clinical research is fueling an exponential
increase in the demand for clinical trials in India. The introduction of
cutting-edge technologies such as Artificial Intelligence (AI), Machine
Learning (ML), and blockchain has not only transformed but revolutionized the
clinical research landscape in the country. These advanced technologies have
proven to be game-changers, expediting the process of data collection,
enhancing data accuracy, and streamlining trial management, thereby
significantly increasing efficiency and reducing costs.
The
tech-driven approach has made India an exceptionally attractive destination for
global pharmaceutical companies and Contract Research Organizations (CROs)
seeking to conduct clinical trials. The integration of advanced technologies in
clinical research has not only enhanced data reliability but has also resulted
in faster trial completion times, leading to quicker regulatory approvals.
This, in turn, further incentivizes more trials to be conducted in the country. India's diverse genetic pool adds another layer of advantage, making
it an ideal location for conducting diverse clinical studies. The ability to
include a wide range of genetic profiles in clinical trials allows for more comprehensive
insights and contributes to the growing demand for clinical research in India.
The
integration of technology in clinical research is not just a passing trend; it
signifies a paradigm shift that is paving the way for more agile, precise, and
patient-centric clinical trials in India. This transformative shift holds
immense potential for advancing medical knowledge, improving patient outcomes,
and ultimately shaping the future of healthcare in the country.
Digitalization
Of Clinical Trials
The
digitalization of clinical trials is expected to have a positive and
transformative impact on market growth. With the advancement of digital
technologies, multiple trial processes such as data capture, regulatory
compliance, logistics and supplies management, and more, have been streamlined,
leading to increased efficiency and effectiveness. This digital revolution has
revolutionized the way clinical trials are conducted, allowing for real-time
data acquisition related to safety and toxicity. The ability to rectify any
issues promptly in trial design has further facilitated market growth.
In
addition to the numerous benefits of digitalization, it is worth noting that
the cost of clinical trials in India is nearly half of that incurred in the
U.S. and Europe. This significant cost efficiency not only attracts global
pharmaceutical companies but also creates a favorable environment for
conducting clinical trials within the country. India offers a
large treatment-naïve patient pool, which is highly valuable for conducting
rigorous and diverse clinical studies. These factors, combined, contribute to
the overall growth of the market and position India as a prominent destination
for clinical research and development.
Segmental Insights
Phase Insights
Based on the phase,
the phase III segment emerged as the leader in terms of revenue share.
This can be attributed to the inherently cost-intensive nature of this phase.
Phase III trials necessitate a substantial patient population, which is one of
the primary reasons for the high cost associated with conducting these trials. The studies conducted in this phase typically span over several
years, unlike phase I and II, which contributes to the overall cost of the
trial and further bolsters the segment's dominance in the market.
On the other
hand, the phase I segment is expected to witness notable growth over the
forecast period, mainly due to the substantial research and development
(R&D) investments made by both global and local pharmaceutical and
biotechnological firms. The increasing demand for novel treatments and
biologics, driven by advancements in medical science and the growing healthcare
needs, further fuels the growth of this segment. When it comes to the different
phases of clinical trials, the market is divided into phase I, phase II, phase
III, and phase IV. Each phase plays a crucial role in the drug development
process.
Phase I primarily focuses on initial safety testing, phase II assesses
the effectiveness of the treatment, phase III evaluates the treatment's
efficacy and safety on a larger scale, and phase IV monitors the drug's
long-term effects after it has been approved and released to the market. The
continuous advancements and innovations in the field of clinical trials
contribute to the overall growth and development of the healthcare industry,
ensuring the availability of safe and effective treatments for patients
worldwide.
Study Design Insights
Based on study
design, the interventional trials segment held the largest revenue share, primarily driven by the adoption of this study design in a large number
of trials. This type of study design, which includes large randomized clinical
trials, is widely recognized as one of the most effective approaches for detecting
small to moderate effects of drugs. It offers robust means of
minimizing the influence of confounding variables, further enhancing its appeal
compared to other clinical study designs.
On the other
hand, the expanded access trials segment is expected to witness a significant
compound annual growth rate (CAGR) during the forecast period. This can be
attributed to various factors, including the rising prevalence of serious
diseases, the increasing demand for innovative treatment options, and the
substantial burden of chronic diseases in the country. These factors
collectively contribute to the growth of the expanded access trials segment,
offering greater opportunities for patients to access novel therapies and
interventions.
Download Free Sample Report
Regional Insights
The
Western region of India is emerging as a dominant force in the India Clinical
Trials Market. With its well-established and state-of-the-art infrastructure
for clinical research, including cutting-edge medical facilities and advanced
laboratories, the region offers a highly conducive and progressive environment
for conducting a wide range of clinical trials.
Maharashtra
boasts a pool of experienced professionals in the field who possess in-depth knowledge
and expertise in various therapeutic areas. These professionals are supported
by a robust network of research institutions and academic centers, fostering
collaboration and innovation in the field of clinical research. The state of Maharashtra has a high patient population, comprising diverse
demographics and a mix of urban and rural communities.
This provides ample
opportunities for recruitment and participation in clinical trials, ensuring a
comprehensive representation of the target population and enhancing the
generalizability of study results. As a result of these favorable factors and
conducive ecosystem, Maharashtra has become the preferred destination for both
domestic and international organizations looking to conduct diverse and
impactful clinical trials in the country. The state's commitment to ethical
practices, regulatory compliance, and patient safety further strengthens its
position as a leading hub for clinical research in India.
Recent Developments
- In November 2025, Tata Consultancy Services launched the next generation of the TCS ADD Risk Based Quality Management platform, adding AI-powered modules for risk assessment, trial analytics, quality tolerance limits, and patient-level data monitoring across the clinical-trial lifecycle.
- In September 2025, Roche Pharma India announced completion of the first phase of its Advanced Inclusive Research (AIR) Site Alliance in India, partnering with 10 government hospitals and training nearly 400 professionals to strengthen clinical-trial capability at public institutions.
- In March 2024, Eli
Lilly and Company (India) Pvt. Ltd. has initiated Phase III clinical trials in
India for an oral medication named orforglipron, intended for weight loss. This
oral drug aims to offer an alternative to injectable weight-loss treatments,
catering particularly to patients with Type 2 diabetes, as well as those
dealing with obesity or overweight and facing heightened risks of
cardiovascular diseases.
- In March 2024, clinical
trials for MTBVAC, a tuberculosis vaccine candidate from Spain and the first
live attenuated vaccine derived from Mycobacterium tuberculosis isolated from a
human, have commenced in India. Hyderabad-based Bharat Biotech is conducting
these trials in collaboration with Biofabri. The trials aim to assess the
safety and immunogenicity of MTBVAC, with a pivotal trial focusing on safety,
immunogenicity, and efficacy scheduled to commence in 2025.
Key Market Players
|
By Phase
|
By Study Design
|
By Indication
|
By Region
|
- Phase I
- Phase II
- Phase III
- Phase IV
|
- Interventional
- Observational
- Expanded Access
|
- Autoimmune
- Blood Disorders
- Pain Management
- Oncology
- CNS Condition
- Diabetes
- Obesity
- Cardiovascular
- Others
|
- North India
- East India
- West India
- South India
|
Report
Scope:
In
this report, the India Clinical Trials Market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
- India Clinical Trials Market, By Phase:
o
Phase I
o
Phase II
o
Phase III
o
Phase IV
- India Clinical Trials Market, By Study Design:
o
Interventional
o
Observational
o
Expanded Access
- India Clinical Trials Market, By Indication:
o
Autoimmune
o
Blood Disorders
o
Pain Management
o
Oncology
o
CNS Condition
o
Diabetes
o
Obesity
o
Cardiovascular
o
Others
- India Clinical Trials Market, By Region:
o
North
o
South
o
West
o
East
Competitive
Landscape
Company
Profiles: Detailed
analysis of the major companies present in the India Clinical Trials Market.
Available
Customizations:
India
Clinical Trials Market report with the given market data, Tech Sci
Research offers customizations according to a company's specific needs. The
following customization options are available for the report:
Company
Information
- Detailed analysis and profiling of
additional market players (up to five).
India Clinical Trials
Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected]